MinuteClinic launches weight-loss program incorporating DASH diet
WOONSOCKET, R.I. — MinuteClinic has created a weight-loss program that incorporates what has been ranked as one of the top diets in the country.
The retail clinic chain, a division of CVS Caremark, called the Weight Loss Program at MinuteClinic a convenient, personalized program to help patients lose weight and live a healthier lifestyle. The program incorporates the DASH diet, ranked as the No. 1 Overall Diet by U.S. News and World Report.
The program includes weekly visits with a MinuteClinic practitioner and nutrition and weight-loss advice delivered through the online DASH for Health program and includes a medical evaluation with lab tests for blood sugar and cholesterol. DASH stands for dietary approaches to stop hypertension. Most insurance plans cover the program, which costs $69 for the first assessment and $59 for subsequent coaching sessions.
"DASH is one of the most highly recommended, evidence-based diets in clinical practice today," MinuteClinic chief medical officer Nancy Gagliano said. "Our weight-loss program is designed to help patients lose weight by making smart choices and focuses on healthy eating with DASH-approved recipes. In addition to providing healthy dietary recommendations, MinuteClinic practitioners tailor a weight-loss plan for each patient that incorporates counseling, education and advice to help patients achieve their goals."
Included in the program is an online membership in DASH for Health, which includes tools, meal plans, exercise tips and recipes. The MinuteClinic program is limited to patients aged 18 and older and is not available in Massachusetts.
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.
Portion Control Tools Like Meal Measure, really work well with The Dash Diet or any portion control Diet see myplate.gov
NASP engages pharmacists, executives, payers, organizations to develop practice parameters
ALEXANDRIA, Va. — The National Association of Specialty Pharmacy will begin developing pharmacy practice parameters in about 20 specialty therapeutic categories this year, the group said.
The NASP said it would engage specialty pharmacists, executives, payers, reimbursement consultants and organizations and patient advocacy groups focused on disease states to develop standards of practice for pharmacists in the targeted therapeutic areas. Parameters also will include information technology and metrics for adherence and outcomes that will allow organizations to use and embellish a set of baseline standards.
"Our goal as an organization is to establish practice standards that encompass clinical guidelines, benefit design and management and information technology to measure adherence and outcomes," NASP CEO Gary Cohen said. "We will collaborate with other stakeholders to utilize existing and emerging guidelines and adapt them to the specific needs of the specialty pharmacy community. Specialty pharmacists are playing a more integral role in the collaborative care model and will be a key driver of successful patient outcomes."
The group said it was recruiting volunteers to work on advisory and consensus groups in different disease categories to support the development of practice parameters.
"All the newly approved specialty pharmaceuticals targeted therapies coming on the market today require highly skilled, specialized pharmacists who have disease and drug-specific training and IT systems to support ongoing concurrent medication treatment management," NASP board member and Onco360 CEO Burt Zweigenhaft said.
No comments found
Acura Pharmaceuticals announces development of advanced meth-resistant pseudoephedrine product
PALATINE, Ill. — Acura Pharmaceuticals on Monday announced a second-generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of methamphetamine hydrochloride when processed in the direct conversion or one-pot method.
“We are excited to advance our IMPEDE technology demonstrating its adaptability to the ever changing meth production problem,” stated Robert Jones, president and CEO of Acura Pharmaceuticals. “Nexafed is the only meth-resistant pseudoephedrine product on the market that meets the Food and Drug Administration’s bioequivalence standards for demonstrated effectiveness. If Nexafed with IMPEDE 2.0 can also meet that standard, we believe we will have a meth-resistant pseudoephedrine product that delivers unmatched performance.”
Acura intends to immediately commence development of an upgraded Nexafed tablet using IMPEDE 2.0.
IMPEDE 2.0 was created through the addition of two new inactive pharmaceutical ingredients to Acura’s existing IMPEDE technology. IMPEDE 2.0 was tested by an outside laboratory using an optimized, high-yield direct conversion test method that is designed to replicate the direct conversion, or one-pot, process commonly utilized by clandestine methamphetamine laboratories.
IMPEDE 2.0 yielded no measurable amount of methamphetamine in its initial testing compared to an approximate 38% yield with the older IMPEDE technology. Acura intends to validate these results and perform its battery of extraction tests on the reformulated NEXAFED tablets.
No comments found